Related Experiment Videos
Effect of age on myocardial infarction and thrombolysis
1Department of Emergency Medicine, MetroHealth Medical Center, Cleveland, OH 44109.
Insights
Elderly patients with acute myocardial infarction benefit from thrombolytic therapy, challenging the notion that advanced age is a contraindication due to perceived risks. Pooled data confirm positive outcomes for older individuals receiving this treatment.
Area of Science:
- Cardiology
- Geriatric Medicine
- Pharmacology
Background:
- Acute myocardial infarction (heart attack) is a leading cause of death in the elderly.
- Thrombolytic therapy is the primary treatment for acute myocardial infarction.
- Advanced age has historically been viewed as a relative contraindication for thrombolytic therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of thrombolytic therapy in elderly patients with acute myocardial infarction.
- To address the trend of under-treating elderly patients due to perceived increased complication risks.
Main Methods:
- Pooled analysis of available data from multiple studies involving elderly patients receiving thrombolytic therapy for acute myocardial infarction.
- Comparison of outcomes between elderly and younger patient groups, or analysis of outcomes within the elderly cohort.
Main Results:
- Elderly patients demonstrate significant benefit from thrombolytic therapy for acute myocardial infarction.
- Available data do not support the perception of an unacceptably increased risk of complications in the elderly.
Conclusions:
- Thrombolytic therapy is beneficial for elderly patients experiencing acute myocardial infarction.
- Age should not be a contraindication to thrombolytic therapy in myocardial infarction management.
- The elderly population stands to gain substantial advantages from timely thrombolytic treatment.
Abstract:
Thrombolytic therapy has emerged as the treatment of choice for patients presenting with an acute myocardial infarction. Myocardial infarction is a major cause of morbidity and mortality in the elderly. Advancing age has been considered a relative contraindication to thrombolytic therapy despite the potential for the elderly to derive the greatest benefit from this therapy. This trend not to treat the elderly has been based on a perceived increased risk of complications. Available data pooled from several studies clearly show that the elderly benefit from thrombolytic therapy.